

From: [Tomczak, Tammy](#)
To: [Pavon, Sandy](#)
Subject: FW: RE: NRC RAM License Amendment
Date: Tuesday, July 06, 2021 9:37:06 AM
Attachments: [image002.png](#)

Hi Sandy,

Can you please add this email to ADAMS?

Thank you!!
Tammy


From: Todd Hockemeyer <thockemeyer@pointbiopharma.com>
Sent: Friday, July 02, 2021 2:51 PM
To: Tran, Frank <Frank.Tran@nrc.gov>
Cc: Tomczak, Tammy <Tammy.Tomczak@nrc.gov>
Subject: [External_Sender] RE: NRC RAM License Amendment

Dear Mr. Tran and Ms. Tomczak,

We respectfully withdraw the NRC Amendment to RAM License 13-35593-01, dated June 29, 2021.

We will be submitting a new amendment per recent direction from Dr. Howe and Mr. Tran.

Best regards,

 POINT Biopharma USA Inc. 4850 West 78 th Street Indianapolis, Indiana 46268 United States	Todd Hockemeyer EVP US Manufacturing Operations (M) 317.543.9957 x301 (F) 289.444.0179 thockemeyer@pointbiopharma.com
--	---

This message, including any attachments, is privileged and may contain confidential information intended only for the addressee/s. If you are not the addressee or an authorized recipient of this message, any distribution, copying, publication or use of this information for any purpose is prohibited. Please notify the sender immediately by e-mail and then delete this message.

From: Tran, Frank <Frank.Tran@nrc.gov>
Sent: Tuesday, June 29, 2021 2:17 PM
To: Todd Hockemeyer <thockemeyer@pointbiopharma.com>
Cc: Tomczak, Tammy <Tammy.Tomczak@nrc.gov>
Subject: RE: NRC RAM License Amendment

[*]

Dear Mr. Hockemeyer:

Thank you for the information. We will look out for your incoming amendment request in the mail.

Sincerely,

Frank Tran

From: Todd Hockemeyer <thockemeyer@pointbiopharma.com>

Sent: Tuesday, June 29, 2021 12:35 PM

To: Tran, Frank <Frank.Tran@nrc.gov>

Subject: [External_Sender] NRC RAM License Amendment

Dear Mr. Tran,

Please see the attached PDF documents for our Volume 7 RAM License Amendment:

Form 313

Cover Letter

Item 5/6 – Isotope Possession Limit: Isotope, Form, Limit and Use (Amended)

Item 9 – Facilities and Equipment (Amended)

I have also sent to the Warrenville Region III Office, two printed copies of the amendment submission.

If you have any questions, please let me know.

Best regards,



[POINT Biopharma USA Inc.](http://POINTBiopharmaUSA.com)

4850 West 78th Street

Indianapolis, Indiana 46268

United States

Todd Hockemeyer

EVP US Manufacturing Operations

(M) 317.543.9957 x301

(F) 289.444.0179

thockemeyer@pointbiopharma.com

This message, including any attachments, is privileged and may contain confidential information intended only for the addressee/s. If you are not the addressee or an authorized recipient of this message, any distribution, copying, publication or use of this information for any purpose is prohibited. Please notify the sender immediately by e-mail and then delete this message.

[*EXTERNAL EMAIL] DO NOT CLICK links or attachments unless you recognize the sender and know the content is safe.